Stellar Biotechnologies Appoints Andrew Saxon, M. D., Chairman - Scientific Advisory Board (SAB)
Port Hueneme, CA - May 11, 2010, Stellar Biotechnologies, Inc. (OTC: SBOTF, TSX-V: KLH) has appointed Dr. Andrew Saxon, a world-renowned expert in human cellular and molecular immunology, Chairman - SAB. Dr. Saxon is Professor & Chief Emeritus, Clinical Immunology/Allergy in the Department of Medicine, David Geffen School of Medicine at UCLA.
Stellar’s CEO, Frank Oakes, said, “It is Stellar’s great fortune to have a physician and research scientist like Dr. Saxon heading up and developing an active Scientific Advisory Board. He is one of the key figures leading the drive to develop a commercial primary human immune response diagnostic based on our important product, KLH -http://en.wikipedia.org/wiki/Keyhole_limpet_hemocyanin. He has also identified leading candidates in protein engineering, therapeutic vaccine and molecular diagnostic development and novel therapeutics to fill out the SAB.”
Dr. Saxon received his medical degree from Harvard Medical School. He is board certified in Internal Medicine, Allergy and Clinical Immunology and Diagnostic/Laboratory Immunology. He has published over 180 peer reviewed research publications primarily dealing with the control and assessment of the human immune response. Dr. Saxon and colleagues at UCLA were the first to recognize AIDS in 1980, brought this new disease to the attention of the CDC in 1981, and published the first research publication describing this disease in the New England Journal of Medicine that same year. Dr. Saxon and his collaborators have made seminal discoveries on the mechanisms that control human antibody responses and particularly allergic antibodies (IgE) as well as pioneered research into the role of environmental factors in the modulation of the human immune response. As part of his work, Dr. Saxon has had extensive experience with the KLH in its various molecular forms in his research. Dr. Saxon is also the Editor-in-Chief of Clinical Immunology, the official journal of the Clinical Immunology Society.
Dr. Saxon said, “I’m really pleased to be able contribute to the growth of this truly exciting and dynamic company. Stellar Biotechnologies is sitting at the nexus of a new era of therapies and diagnostics driven by what I believe will be ever growing use of its key product, KLH, a potent, yet safe, molecule that can be used to both drive the immune system as well as assess the immune systems functional status. Because of the unique properties of KLH, an expanding number of researchers and scientists in academia, biotech and Pharma are finding novel and amazing uses for it. I believe an active SAB can enhance growth as well as help direct the board and executives to new markets and expanded use of this rare, naturally-sourced molecule and important medical reagent.”
www.StellarBiotechnologies.com
Contact:
Darrell Brookstein, VP
dbrookstein@stellarbiotech.com
About Stellar Biotechnologies, Inc (TSX-V: KLH): Stellar’s product, KLH, is a potent immuno-stimulatory protein with an exceptional record of safety and non-toxicity in humans that is being used in medicines known as conjugate therapeutic vaccines and in other biomedical products. Already a world leader in the production of KLH, Stellar plans to further monetize its KLH production platform and maximize the commercial impact of its intellectual property portfolio through the physical sourcing, purification and supply of medical-grade KLH. KLH is exclusively sourced from the blood of the rare keyhole limpet and Stellar has technology for the maintenance of that animal, as well as a non-lethal extraction method of the critical molecule and refinement process for KLH that it currently sells into growing academic, research, pharmaceutical markets.
Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
